Phase I multicenter, open-label, first-in-human study of BMS-986497 (ORM-6151) as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in subjects with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Every Breakthrough
Begins With You

Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

Learn more about Only Possible Here

Donate Today